Comparison · NCT04847557-sae
Tirzepatide - MTD vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Tirzepatide - MTD vs Placebo: serious adverse events. Trial comparisons, record NCT04847557-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04847557-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.264 | 0.221 | 0.311 | wilson | |
| Risk in group 2 | 0.256 | 0.214 | 0.303 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00761 | -0.0559 | 0.071 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.03 | 0.806 | 1.32 | log | |
| Odds ratio, group 1 over group 2 | 1.04 | 0.747 | 1.45 | log | |
| Number needed to harm, for one more participant with a serious adverse event on Tirzepatide - MTD than on Placebo | 131 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Tirzepatide - MTD | Participants received a starting dose of 2.5 mg tirzepatide administered SC QW and escalated by 2.5 mg every 4 weeks to a maximum of 15 mg QW or MTD tolerated by the participant (5 mg QW or 10 mg QW). | 96 | 364 | EG000 |
| Group 2 | Placebo | Participants received placebo administered SC QW. | 94 | 367 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Baseline Up To 162 Weeks
Source ClinicalTrials.gov
Trial
- Title
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
- NCT number
- NCT04847557
- Phases
- PHASE3
- Conditions
- Obesity, Heart Failure With Preserved Ejection Fraction (HFpEF)
- Interventions
- Tirzepatide, Placebo
- Lead sponsor
- Eli Lilly and Company
- Results first posted
- 2025-08-20
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04847557?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04847557-sae